Literature DB >> 21924251

Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands.

Erin K Shanle1, John R Hawse, Wei Xu.   

Abstract

Estrogen signaling is mediated by two estrogen receptors (ERs), ERα and ERβ, which have unique roles in the regulation of breast cancer cell proliferation. ERα induces proliferation in response to estrogen and ERβ inhibits proliferation in breast cancer cells, suggesting that ERβ selective ligands may be beneficial for promoting the anti-proliferative action of ERβ. Subtype selective ligands can be identified using transcriptional assays, but cell lines in which ERα or ERβ are independently expressed are required. Of the available reporter cell lines, none have been generated in breast cancer cells to identify subtype selective ligands. Here we describe the generation of two isogenic breast cancer cell lines, Hs578T-ERαLuc and Hs578T-ERβLuc, with stable integration of an estrogen responsive luciferase reporter gene. Hs578T-ERαLuc and Hs578T-ERβLuc cell lines are highly sensitive to estrogenic chemicals and ER subtype selective ligands, providing a tool to characterize the transcriptional potency and subtype selectivity of estrogenic ligands in the context of breast cancer cells. In addition to measuring reporter activity, ERβ target gene expression and growth inhibitory effects of ERβ selective ligands can be determined as biological endpoints. The finding that activation of ERβ by estrogen or ERβ selective natural phytoestrogens inhibits the growth of Hs578T-ERβ cells implies therapeutic potential for ERβ selective ligands in breast cancer cells that express ERβ. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21924251      PMCID: PMC3210412          DOI: 10.1016/j.bcp.2011.08.026

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  41 in total

1.  A comparison of transcriptional activation by ER alpha and ER beta.

Authors:  S M Cowley; M G Parker
Journal:  J Steroid Biochem Mol Biol       Date:  1999 Apr-Jun       Impact factor: 4.292

2.  MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial.

Authors:  Deborah Grady; George F Sawaya; Karen C Johnson; William Koltun; Rachel Hess; Eric Vittinghoff; Margaret Kristof; Mary Tagliaferri; Isaac Cohen; Kristine E Ensrud
Journal:  Menopause       Date:  2009 May-Jun       Impact factor: 2.953

3.  Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists.

Authors:  S R Stauffer; C J Coletta; R Tedesco; G Nishiguchi; K Carlson; J Sun; B S Katzenellenbogen; J A Katzenellenbogen
Journal:  J Med Chem       Date:  2000-12-28       Impact factor: 7.446

4.  Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells.

Authors:  Edmund C Chang; Jonna Frasor; Barry Komm; Benita S Katzenellenbogen
Journal:  Endocrinology       Date:  2006-06-29       Impact factor: 4.736

Review 5.  Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action.

Authors:  Erin K Shanle; Wei Xu
Journal:  Chem Res Toxicol       Date:  2010-11-05       Impact factor: 3.739

Review 6.  Estrogen receptors: therapies targeted to receptor subtypes.

Authors:  S Nilsson; J-Å Gustafsson
Journal:  Clin Pharmacol Ther       Date:  2010-12-01       Impact factor: 6.875

7.  Estrogen receptor beta expression in invasive breast cancer.

Authors:  S Mann; R Laucirica; N Carlson; P S Younes; N Ali; A Younes; Y Li; M Younes
Journal:  Hum Pathol       Date:  2001-01       Impact factor: 3.466

8.  Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.

Authors:  Naoko Honma; Rie Horii; Takuji Iwase; Shigehira Saji; Mamoun Younes; Kaiyo Takubo; Masaaki Matsuura; Yoshinori Ito; Futoshi Akiyama; Goi Sakamoto
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

9.  Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications.

Authors:  N Brünner; V Boulay; A Fojo; C E Freter; M E Lippman; R Clarke
Journal:  Cancer Res       Date:  1993-01-15       Impact factor: 12.701

10.  Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.

Authors:  Frank J Secreto; David G Monroe; Shamit Dutta; James N Ingle; Thomas C Spelsberg
Journal:  J Cell Biochem       Date:  2007-08-01       Impact factor: 4.429

View more
  11 in total

1.  Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.

Authors:  Diana C Márquez-Garbán; Gang Deng; Begonya Comin-Anduix; Alejandro J Garcia; Yanpeng Xing; Hsiao-Wang Chen; Gardenia Cheung-Lau; Nalo Hamilton; Michael E Jung; Richard J Pietras
Journal:  J Steroid Biochem Mol Biol       Date:  2019-06-19       Impact factor: 4.292

2.  Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target.

Authors:  Jae Hak Lee; Olaf Peters; Lutz Lehmann; Carmen S Dence; Terry L Sharp; Kathryn E Carlson; Dong Zhou; M Jeyakumar; Michael J Welch; John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2012-06-30       Impact factor: 2.408

3.  Thiophene-core estrogen receptor ligands having superagonist activity.

Authors:  Jian Min; Pengcheng Wang; Sathish Srinivasan; Jerome C Nwachukwu; Pu Guo; Minjian Huang; Kathryn E Carlson; John A Katzenellenbogen; Kendall W Nettles; Hai-Bing Zhou
Journal:  J Med Chem       Date:  2013-04-15       Impact factor: 7.446

4.  Prognostic significance of full-length estrogen receptor beta expression in stage I-III triple negative breast cancer.

Authors:  Erin K Shanle; Adedayo A Onitilo; Wei Huang; KyungMann Kim; Chong Zang; Jessica M Engel; Wei Xu; Kari B Wisinski
Journal:  Am J Transl Res       Date:  2015-07-15       Impact factor: 4.060

5.  Differential action of monohydroxylated polycyclic aromatic hydrocarbons with estrogen receptors α and β.

Authors:  Chelsie K Sievers; Erin K Shanle; Christopher A Bradfield; Wei Xu
Journal:  Toxicol Sci       Date:  2012-09-18       Impact factor: 4.849

6.  Reciprocal Regulation of ERα and ERβ Stability and Activity by Diptoindonesin G.

Authors:  Zibo Zhao; Lu Wang; Taryn James; Youngeun Jung; Ikyon Kim; Renxiang Tan; F Michael Hoffmann; Wei Xu
Journal:  Chem Biol       Date:  2015-12-03

7.  Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells.

Authors:  Erin K Shanle; Zibo Zhao; John Hawse; Kari Wisinski; Sunduz Keles; Ming Yuan; Wei Xu
Journal:  Mol Endocrinol       Date:  2013-08-26

Review 8.  Reporter Cell Lines for the Characterization of the Interactions between Human Nuclear Receptors and Endocrine Disruptors.

Authors:  Marina Grimaldi; Abdelhay Boulahtouf; Vanessa Delfosse; Erwan Thouennon; William Bourguet; Patrick Balaguer
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-11       Impact factor: 5.555

Review 9.  Phytochemicals Targeting Estrogen Receptors: Beneficial Rather Than Adverse Effects?

Authors:  Sylvain Lecomte; Florence Demay; François Ferrière; Farzad Pakdel
Journal:  Int J Mol Sci       Date:  2017-06-28       Impact factor: 5.923

10.  Cosmosiin Increases ADAM10 Expression via Mechanisms Involving 5'UTR and PI3K Signaling.

Authors:  Zhuo Min; Ying Tang; Xiao-Tong Hu; Bing-Lin Zhu; Yuan-Lin Ma; Jing-Si Zha; Xiao-Juan Deng; Zhen Yan; Guo-Jun Chen
Journal:  Front Mol Neurosci       Date:  2018-06-11       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.